Breast MR Imaging for the Assessment of Residual Disease Following Initial Surgery for Breast Cancer with Positive Margins
Overview
Authors
Affiliations
Objectives: To determine the accuracy of post-operative MR in predicting residual disease in women with positive margins, emphasizing the size thresholds at which residual disease can be confidently identified.
Methods: This IRB-approved HIPAA-compliant retrospective study included 175 patients with MR after positive margins following initial surgery for breast cancer. Two expert readers independently re-evaluated MR images for evidence of residual disease at the surgical cavity and multifocal/multicentric disease. All patients underwent definitive surgery and MR findings were correlated to histopathology.
Results: 139/175 (79.4%) patients had residual disease at surgery. Average overall sensitivity, specificity, PPV and NPV for residual disease at the surgical cavity were 73%, 72%, 91% and 45%, respectively. The readers identified 42/45 (93%, reader 1) and 43/45 (95%, reader 2) patients with residual invasive disease at the cavity of ≥5 mm and 22/22 (100%, both readers) patients with disease ≥10 mm. Average sensitivity, specificity, PPV and NPV for unknown multifocal/multicentric disease were 90%, 96%, 93% and 86%, respectively.
Conclusions: Post-operative breast MR can accurately depict ≥5-mm residual disease at the surgical cavity and unsuspected multifocal/multicentric disease. These findings have the potential to lead to more appropriate selection of second surgical procedures in women with positive margins.
Key Points: • Post-operative breast MRI accurately defines residual disease of ≥5 mm. • Surgical cavity sensitivities were high for both invasive carcinoma and DCIS. • Post-surgical changes and very small residual disease (<5 mm) may overlap. • Post-operative breast MRI may help planning an accurate re-resection.
Tong Y, Hu Z, Wang H, Huang J, Zhan Y, Chai W Eur Radiol. 2024; 34(8):5477-5486.
PMID: 38329503 PMC: 11255056. DOI: 10.1007/s00330-024-10609-7.
Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer.
Pavuluri K, Yang E, Ayyappan V, Sonkar K, Tan Z, Tressler C Theranostics. 2022; 12(4):1937-1951.
PMID: 35198081 PMC: 8825591. DOI: 10.7150/thno.53147.
Healy N, Benson J, Sinnatamby R BJR Open. 2021; 3(1):20210024.
PMID: 34381952 PMC: 8327930. DOI: 10.1259/bjro.20210024.
Understanding indications and defining guidelines for breast magnetic resonance imaging.
Schoub P SA J Radiol. 2019; 22(2):1353.
PMID: 31754513 PMC: 6837823. DOI: 10.4102/sajr.v22i2.1353.